Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. A…
treatment
This week’s column focuses on stories from Multiple Sclerosis News Today reporters who have been following the annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS. #ECTRIMS2021 – Stem Cell Transplant May Better Treat SPMS Than DMTs This presentation involves autologous…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Early use of…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. The investigational anti-CD20…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Sativex…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Mavenclad…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People with …
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference.
In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked Meghan Beier, PhD, a rehabilitation neuropsychologist who teaches skills and techniques to improve patients’ quality of life, to answer some of your questions related to fatigue for people with multiple sclerosis (MS). Beier is a psychologist specializing…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the…
The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation of arsenic trioxide, for the treatment of relapsing-remitting multiple sclerosis (RRMS). Once issued, the patent will protect Arscimed’s use for this indication until 2037. This will add to the already…
Deep Brain Stimulation May Help With MS-associated Tremors Deep brain stimulation (DBS) has been used to treat people with Parkinson’s disease and essential tremor, and in some cases, those with MS who have severe tremors, when other treatments have failed. The treatment involves implanting electrodes in the brain so…
The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…
Would you sign up for healthcare from the place where you buy books, bluejeans, and bagels? Amazon thinks you might, and the company is moving closer to becoming the doctor in your house, according to a report last month by Insider. Amazon has been dabbling in the healthcare business…
Treatment with hydroxychloroquine, an anti-malaria medication, appeared to help slow disability progression among people with primary-progressive multiple sclerosis (PPMS) in a small, proof-of-concept clinical trial. Hydroxychloroquine “is a promising treatment candidate for PPMS and should be investigated further in randomized controlled clinical trials,” its researchers wrote. Results of the study…
People in Australia with multiple sclerosis (MS) and certain other medical conditions will have access to new and expanded medications — including Kesimpta — now listed on the Pharmaceutical Benefits Scheme (PBS). Having these medications on the PBS will lower treatment costs for MS patients and their…
I am having an MS relapse, my first in three years. In the first two years after I was diagnosed with relapsing-remitting MS in early 2017, I relapsed every two or three months. It got to the point that I couldn’t tell where one relapse began and another ended.
Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well tolerated, according to an analysis of trial data in…
Deep brain stimulation (DBS) effectively reduces tremors in people with multiple sclerosis (MS), but may lead to worsening symptoms and speech problems, according to a review study. While these findings support the use of DBS for treating this common, disabling MS symptom, larger studies using standardized measures of…
Ublituximab, Potential Relapsing MS Therapy, Up for FDA Approval Like Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), ublituximab targets the CD20 protein that’s found on the surface of B-cells in the immune system. It then binds to it and kills the cell, reducing the number of cells that are attacking the…
Mutations in the John Cunningham virus may serve as an early predictor for a rare brain infection in multiple sclerosis patients receiving Tysabri (natalizumab), a study suggests. However, more research is required to investigate the specific mutations in the viral VP1 gene, and validate the risk of the…
Increasing the activity of a gene called Myc can make oligodendrocyte precursor cells, or the cells that repair myelin, more efficient — “ground-breaking research” that could have implications for advancing MS treatments, according to a new study by Cambridge researchers. The study, “Myc determines the functional age…
Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the company’s two identically-designed Phase 3 trials, dubbed…
People living with multiple sclerosis know that the medications used to treat it are expensive. According to the National Multiple Sclerosis Society, the median annual price of brand-name disease-modifying therapies (DMTs) last year was $91,835. Five of them carried a price tag of more than $100,000 a year. Many pharmaceutical…
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational anti-CD20 monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). Its application was based on data from the ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) Phase…
An upcoming conference focused on progressive multiple sclerosis (MS) will offer the latest insights about the underlying biology of the disease, and treatment and clinical strategies in development. The one-day conference, “Emerging Research & Trial Strategies for Progressive Multiple Sclerosis,” is taking place virtually on Oct. 4,and is…
A partnership will allow NervGen to use Imeka‘s proprietary biomarker imaging technology to precisely measure changes in the brain and spinal cord in its upcoming clinical trials, including a study of NVG-291 in people with multiple sclerosis (MS) NervGen plans to initiate Phase 1b/2 trials into its lead candidate for neural…
Cognitive rehabilitation is an effective therapy for cognitive problems brought on by multiple sclerosis (MS), a review study highlights. “Clinicians should consider this low-cost, low-risk, yet effective treatment approach for their patients,” its researchers wrote. The study, “Neurological update: cognitive rehabilitation in multiple sclerosis,” was published…
Oral Fesoterodine Fumarate Can Ease Bladder Problems in MS This is a biggie for me since bladder problems have affected my quality of life for years. I recently switched my bladder medication hoping it would be a change for the better. The jury is still out. So, I’ll have…
The first patient who completed the ProTEct-MS Phase 2 clinical trial assessing temelimab as a treatment for relapsing forms of multiple sclerosis (MS) has entered the trial’s extension part. In the open-label extension trial, patients will switch to or continue to receive temelimab at least until next spring, when…